Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $202 from $200 and keeps an Outperform rating on the shares. The company reported strong Q3 results with sales beats for both Auvelity and Sunosi, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics management to meet with Truist
- Axsome Therapeutics’ Earnings Call Highlights Growth and Challenges
- Axsome Therapeutics price target raised to $198 from $189 at RBC Capital
- Axsome Therapeutics price target raised to $185 from $180 at H.C. Wainwright
- Axsome Therapeutics price target raised to $196 from $194 at Morgan Stanley